Harbour BioMed successfully doses antiCTLA-4 antibody

By The Science Advisory Board staff writers

January 25, 2022 -- Harbour BioMed has successfully completed dosing of the first patient in a phase IB/IIA trial at the stage of dose expansion of its anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, HBM4003, in combination therapy with toripalimab, an antiprogrammed cell death protein 1 (PD-1) antibody, for patients suffering from advanced melanoma and solid tumors.

The antibody showed a good safety profile and strong efficacy in the monotherapy study of the phase I trial, according to the company. Harbour BioMed is seeking to conduct studies of HBM4003 in combination therapy as a treatment for multiple solid tumors, including melanoma, non-small cell lung cancer, hepatocellular carcinoma, neuroendocrine tumors, and neuroendocrine carcinoma.

HBM4003 is a fully human antiCTLA-4 monoclonal heavy chain-only antibody generated from Harbour mice. By enhancing antibody-dependent cell cytotoxicity-killing activity, the antibody can improve depletion specific to high CTLA-4 Treg cells in tumor tissues, the firm said.

Harbour BioMed is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics that are focused on immunology and oncology.

Copyright © 2022 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here